Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
139
Recruiting, industry sponsors, Immunology and inflammation, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting139
- Completed1,148
139 trials
Showing 1 to 25, recently updated first.
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseasePivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06548542 · 590 participants (planned) · Start Sep 4, 2024 · Primary completion Jan 2030
Drug: Risankizumab; Lutikizumab and 4 more · For: Crohn's Disease
Sites: Dothan, Alabama; Mobile, Alabama; Coronado, California · 255 sites in all
- A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid ArthritisPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07276581 · 320 participants (planned) · Start Dec 15, 2025 · Primary completion Nov 12, 2027
Drug: AZD1163 · For: Rheumatoid Arthritis
Sites: Glendale, Arizona; Prescott Valley, Arizona; Tucson, Arizona · 147 sites in all
- A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's DiseaseRecruiting
SanofiSanofi (SNY)
NCT06958536 · 99 participants (planned) · Start Jun 3, 2025 · Primary completion Dec 17, 2026
Drug: brivekimig; Placebo · For: Crohn's Disease
Sites: Fairhope, Alabama; Tucson, Arizona; Escondido, California · 78 sites in all
- A Study of E6742 in Participants With Systemic Lupus ErythematosusPivotal-lookingRecruiting
Eisai Co., Ltd.Eisai
NCT07515014 · 256 participants (planned) · Start Mar 31, 2026 · Primary completion Aug 5, 2028
Drug: E6742 · For: Systemic Lupus Erythematosus
Sites: Bengbu, China; Beijing, China; Chongqing, China · 63 sites in all
- A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic DermatitisPivotal-lookingRecruiting
Inmagene LLCIndustry
NCT07037901 · 405 participants (planned) · Start Jun 17, 2025 · Primary completion Dec 2027
Drug: IMG-007; Placebo · For: Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema
Sites: Lancaster, California; Los Angeles, California; Ocala, Florida · 33 sites in all
- Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem CellsRecruiting
Shenzhen Beike Bio-Technology Co., Ltd.Industry
NCT07041801 · 58 participants (planned) · Start Feb 15, 2025 · Primary completion Sep 5, 2027
Drug: hUC-MSCs treatment (low dose); hUC-MSCs treatment (medium dose) and 3 more · For: Systemic Lupus Erythematosus (SLE)
Sites: Shenzhen, China
- A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative ColitisPivotal-lookingRecruiting
Spyre Therapeutics, Inc.Industry
NCT07012395 · 645 participants (planned) · Start May 27, 2025 · Primary completion Jun 2027
Drug: SPY001; SPY002 and 1 more · For: Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis and 1 more
Sites: Canoga Park, California; La Jolla, California; Lancaster, California · 279 sites in all
Diabetes Free, Inc.Industry
NCT07946367 · 72 participants (planned) · Start Dec 1, 2026 · Primary completion Aug 2028
Drug: DFI205 bispecific antibody · For: Rheumatoid Arthritis (RA); Systemic Lupus Erythematosus (SLE); Systemic Sclerosis (SSc) and 1 more
Sites: Erlangen, Germany
AstraZenecaAstraZeneca (AZN)
NCT06897930 · 150 participants (planned) · Start Apr 21, 2025 · Primary completion May 1, 2029
Drug: AZD0120; Cyclophosphamide and 1 more · For: Lupus Erythematosus, Systemic
Sites: San Francisco, California; Stanford, California; Tampa, Florida · 20 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07412704 · 84 participants (planned) · Start Oct 6, 2026 · Primary completion Oct 30, 2029
Drug: BMS-986528 · For: Arthritis, Rheumatoid
Sites: La Jolla, California; Loma Linda, California; Palo Alto, California · 39 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07137598 · 160 participants (planned) · Start Dec 5, 2025 · Primary completion Apr 17, 2027
Drug: Afimkibart; Placebo · For: Rheumatoid Arthritis
Sites: Avondale, Arizona; Peoria, Arizona; La Jolla, California · 66 sites in all
- An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid ArthritisPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07620392 · 120 participants (planned) · Start Jun 3, 2026 · Primary completion Jul 8, 2033
Drug: Afimkibart · For: Rheumatoid Arthritis
Sites: Tamarac, Florida; Lake Charles, Louisiana; Houston, Texas · 17 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07598396 · 30 participants (planned) · Start May 25, 2026 · Primary completion Aug 11, 2028
Drug: Mosunetuzumab · For: Lupus; Systemic Lupus Erythematosus; Lupus Nephritis
Sites: CABA, Argentina; Buenos Aires, Argentina; Salvador, Brazil · 24 sites in all
- A Study of SL-325 in Crohn's Disease PatientsPivotal-lookingRecruiting
Shattuck Labs, Inc.Industry
NCT07753850 · 232 participants (planned) · Start Nov 9, 2026 · Primary completion Jul 2028
Drug: SL-325; Placebo · For: Crohn's Disease
Sites: Little Rock, Arkansas; Oxnard, California; Temple City, California · 20 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT06636656 · 80 participants (planned) · Start Dec 11, 2024 · Primary completion Jul 30, 2027
Drug: BI 3032950 intravenous (Part A); BI 3032950 subcutaneous (Part B) · For: Ulcerative Colitis
Sites: Scottsdale, Arizona; Colorado Springs, Colorado; Kissimmee, Florida · 42 sites in all
- A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
Palisade BioIndustry
NCT07845487 · 204 participants (planned) · Start Aug 28, 2026 · Primary completion Oct 2027
Drug: PALI-2108; PALI-2108 and 1 more · For: Ulcerative Colitis (UC); Severe Ulcerative Colitis; Moderate Ulcerative Colitis
Sites: Sun City, Arizona; San Diego, California; Bristol, Connecticut · 114 sites in all
- Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)Pivotal-lookingRecruiting
Nanjing Immunophage Biotech Co., LtdIndustry
NCT07535489 · 144 participants (planned) · Start Aug 27, 2026 · Primary completion Dec 1, 2028
Drug: IPG11406; Placebo · For: Moderately to Severely Active Ulcerative Colitis (UC)
Sites: Beijing, China
- A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07463183 · 100 participants (planned) · Start Mar 24, 2026 · Primary completion Oct 28, 2027
Drug: MK-8690 · For: Colitis Ulcerative; Ulcerative Colitis
Sites: Anaheim, California; Coronado, California; Colorado Springs, Colorado · 43 sites in all
- A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Pivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07409181 · 405 participants (planned) · Start Apr 20, 2026 · Primary completion Feb 4, 2029
Drug: BI 3000202; Placebo · For: Systemic Lupus Erythematosus
Sites: Beverly Hills, California; La Palma, California; San Diego, California · 139 sites in all
- Study of Afimetoran in Adults With Cutaneous Lupus ErythematosusPivotal-lookingRecruiting
Beeline Medicines CorporationIndustry
NCT07881120 · 390 participants (planned) · Start Nov 3, 2026 · Primary completion Apr 2030
Drug: Afimetoran; Placebo · For: Cutaneous Lupus Erythematosus (CLE); Systematic Lupus Erythematosus
Sites: San Diego, California; DeBary, Florida; Missoula, Montana
AstraZenecaAstraZeneca (AZN)
NCT07295847 · 27 participants (planned) · Start Jan 9, 2026 · Primary completion Feb 22, 2028
Drug: AZD0120; SOC · For: Systemic Sclerosis; Idiopathic Inflammatory Myopathies; Rheumatoid Arthritis
Sites: Tucson, Arizona; Duarte, California; Stanford, California · 27 sites in all
- A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic ArthritisPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07801495 · 220 participants (planned) · Start Oct 19, 2026 · Primary completion Dec 13, 2028
Drug: DDY391; Placebo · For: Moderate to Severe Psoriatic Arthritis
Sites: Huntington Beach, California; Duncansville, Pennsylvania; Philadelphia, Pennsylvania · 8 sites in all
- A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar PustulosisPivotal-lookingRecruiting
LEO PharmaIndustry
NCT07013201 · 135 participants (planned) · Start Sep 11, 2025 · Primary completion Jun 4, 2027
Drug: Delgocitinib cream; Vehicle cream · For: Palmoplantar Pustulosis
Sites: Fountain Valley, California; Douglasville, Georgia; West Bloomfield, Michigan · 40 sites in all
- Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06865105 · 300 participants (planned) · Start Apr 11, 2025 · Primary completion Aug 2029
Drug: Lutikizumab; Risankizumab and 2 more · For: Psoriatic Arthritis
Sites: Huntington Beach, California; Avon Park, Florida; Clearwater, Florida · 41 sites in all
PTC TherapeuticsIndustry
NCT07779616 · 75 participants (planned) · Start Sep 24, 2026 · Primary completion Sep 30, 2027
Drug: PTC844; Placebo · For: Rheumatoid Arthritis
Sites: Chandler, Arizona; Flagstaff, Arizona; Phoenix, Arizona · 26 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.